| Drug Name |
Nalmefene |
| Drug ID |
BADD_D01522 |
| Description |
Nalmefene is a 6-methylene analogue of naltrexone and opioid system modulator but with no opioid activity [FDA Label]. It mediates a partial agonist effect on kappa receptors [A31301]. It is primarily used in the management of alcohol dependence in adult patients in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption [L1024] when it is exists as the hydrochloride dihydrate form under the trade name Selincro. Selincro is orally administered as tablets. Nalmefene works to reduce alcohol consumption in individuals by positive reward effect of alcohol which involves the opioid system, as well as the sedative and dysphoric properties of alcohol [A31301].
It is also indicated to prevent or reverse the effects of opioids, including respiratory depression, sedation, and hypotension by acting on the opioid receptor as an antagonist [FDA Label] under the trade name Revex for intramuscular, intravenous and subcutaneous injection, where nalmefene hydrochloride is an active ingredient. |
| Indications and Usage |
Indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms and who do not require immediate detoxification [L1024].
Indicated for the complete or partial reversal of opioid drug effects, including respiratory depression - induced by either natural or synthetic opioids - or in the management of known or suspected opioid overdose [FDA Label]. |
| Marketing Status |
approved; investigational; withdrawn |
| ATC Code |
N07BB05 |
| DrugBank ID |
DB06230
|
| KEGG ID |
D05111
|
| MeSH ID |
C038981
|
| PubChem ID |
5284594
|
| TTD Drug ID |
D05VIL
|
| NDC Product Code |
82712-1002 |
| UNII |
TOV02TDP9I
|
| Synonyms |
nalmefene | Revex | Selincro | 6-desoxy-6-methylenenaltrexone | nalmefene hydrochloride |
